Amendments to the Claims:

This listing of clams will replace all prior versions, and listings, of claims in the application:

Listing of Claims

Claim 1. (Currently Amended) A compound of the formula I:



I

wherein:

R^1 is ~~selected from the group consisting of:~~

~~(1) hydrogen,~~

~~(2)~~ R^4-$S(O)_pN(R^5)$-,

wherein R^4 is independently selected from the group consisting of:

(a) -C_{1-8}alkyl, which is unsubstituted or substituted with 1-6 fluoro,

(b) -NR^5R^6,

(c) phenyl, and

(d) benzyl,

wherein R^5 and R^6 are independently selected from the group consisting of:

(a) hydrogen,

(b) -C_{1-6}alkyl, which is unsubstituted or substituted with 1-6 fluoro,

(c) phenyl, and

(d) benzyl,

and wherein p is independently 0, 1, or 2;

~~(3) —CN,~~

~~(4) —C_{1-6}alkyl-CN,~~

~~(5) —halogen,~~

~~(6) —phenyl, which is unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from:~~

~~(a) —CN,~~

~~(b) —halo,~~

~~(c) —C_{1-6}alkyl,~~

~~(d) —O R^5;~~

~~(e) —CO_2R^5, and~~

~~(f) —$C(O)R^5$;~~

~~(7)~~



~~wherein n is 1, 2, 3 or 4;~~

R^2 is selected from the group consisting of:

(1) hydrogen,

(2) -C_{1-6}alkyl, -C_{2-6}alkenyl, -C_{2-6}alkynyl, or -C_{3-8}cycloalkyl which is unsubstituted or substituted with 1-7 substituents where the substituents are independently selected from:

(a) halo,

(b) hydroxy,

(c) -O-C_{1-6}alkyl,

(d) -C_{3-6}cycloalkyl,

(e) -$S(O)_p$-C_{1-6}alkyl,

(f) -CN,

(g) -CO_2H,

(h) -CO_2-C_{1-6}alkyl,

(i) -CO-NR^5R^6,

(j) phenyl, which is unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from:

(i) -C_{1-6}alkyl,

(ii) -CN,
(iii) halo,
(iv) $-CF_3$,
(v) $-O-R^5$, and
(vi) $-CO_2R^5$,

(3) phenyl which is unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from:
(a) $-C_{1-6}$alkyl,
(b) -CN,
(c) halo,
(d) $-CF_3$,
(e) $-O-R^5$, and
(f) $-CO_2R^5$;

R^3 is selected from the group consisting of:
(1) hydrogen,
(2) $-C_{1-6}$alkyl, $-C_{2-6}$alkenyl, $-C_{2-6}$alkynyl, or $-C_{3-8}$cycloalkyl which is unsubstituted or substituted with 1-7 substituents where the substituents are independently selected from:
(a) halo,
(b) hydroxy,
(c) $-O-C_{1-6}$alkyl,
(d) $-C_{3-6}$cycloalkyl,
(e) phenyl or pyridyl, which is unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from:
(i) $-C_{1-6}$alkyl,
(ii) -CN,
(iii) halo,
(iv) $-CF_3$,
(v) $-O-R^5$, and
(vi) $-CO_2R^5$,
(f) $-S(O)_pN(R^5)-C_{1-6}$alkyl, and
(g) $-S(O)_pN(R^5)-$ phenyl,

(3) phenyl which is unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from:

(a) -C_{1-6}alkyl,

(b) -CN,

(c) halo,

(d) -CF_3,

(e) -O-R^5, and

(f) -CO_2R^5;

X is selected from the group consisting of:

(1) -CH_2-, and

(2) -O-;

and pharmaceutically acceptable salts thereof.

Claim 2 (Original) The compound of Claim 1 of the formula II:



II .

Claim 3 (Original) The compound of Claim 2 wherein:

R^1 is selected from:

(1) CH_3-$S(O)_2N(CH_3)$-;

(2) CH_3CH_2-$S(O)_2N(CH_3)$-;

(3) $(CH_3)_2CH$-$S(O)_2N(CH_3)$-;

(4) phenyl-$S(O)_2N(CH_3)$-; and

(5) $(CH_3)_2N\text{-}S(O)_2N(CH_3)$-;

R^2 is -$C_{1\text{-}6}$alkyl, unsubstituted or substituted with cyclopropyl or halo;

R^3 is -$C_{1\text{-}6}$alkyl or -$C_{3\text{-}8}$cycloalkyl; and

X is $-CH_2-$ or -O-;

and pharmaceutically acceptable salts thereof.

Claim 4 (Original) The compound of Claim 1 of the formula III:



III .

Claim 5 (Original) The compound of Claim 1 wherein:

R^1 is selected from:

(1) $CH_3\text{-}S(O)_2N(CH_3)$-;

(2) $CH_3CH_2\text{-}S(O)_2N(CH_3)$-;

(3) $(CH_3)_2CH\text{-}S(O)_2N(CH_3)$-;

(4) phenyl-$S(O)_2N(CH_3)$-; and

(5) $(CH_3)_2N\text{-}S(O)_2N(CH_3)$-;

R^2 is -$C_{1\text{-}6}$alkyl, unsubstituted or substituted with cyclopropyl or halo;

R^3 is -$C_{1\text{-}6}$alkyl or -$C_{3\text{-}8}$cycloalkyl; and

X is $-CH_2-$ or -O-;

and pharmaceutically acceptable salts thereof.

Claim 6 (Original) The compound of Claim 1 wherein:

R^1 is $R^4\text{-}S(O)_2N(R^5)$-,

wherein R^4 is independently selected from the group consisting of:

(a) -C_{1-6}alkyl, which is unsubstituted or substituted with 1-6 fluoro,

(b) phenyl, and

(c) benzyl,

and wherein R^5 is independently selected from the group consisting of:

(a) hydrogen,

(b) -C_{1-6}alkyl, which is unsubstituted or substituted with 1-6 fluoro,

(c) phenyl, and

(d) benzyl.

Claim 7 (Original) The compound of Claim 6 wherein R^1 is selected from:

(1) CH_3-$S(O)_2N(CH_3)$-;

(2) CH_3CH_2-$S(O)_2N(CH_3)$-;

(3) $(CH_3)_2CH$-$S(O)_2N(CH_3)$-; and

(4) phenyl-$S(O)_2N(CH_3)$-;

(5) $(CH_3)_2N$-$S(O)_2N(CH_3)$-.

Claim 8 (Original) The compound of Claim 7 wherein R^1 is CH_3-$S(O)_2N(CH_3)$-.

Claim 9 (Original) The compound of Claim 1 wherein R^2 is -C_{1-6}alkyl, unsubstituted or substituted with cyclopropyl or halo.

Claim 10 (Original) The compound of Claim 9 wherein R^2 is selected from:

(1) CH_3-;

(2) CH_3CH_2-;

(3) $(CH_3)_2CH$-;

(4) $CH_3CH_2CH_2$-;

(5) $(CH_3)_2CHCH_2$-;

(6) $CH_3CH_2CH_2CH_2$-;

(7) $CH_3CH_2CH_2CH_2CH_2$-;

(8) cyclopropyl-CH_2-;

(9) CF_3CH_2-; and

(10) CH_2FCH_2-.

Claim 11 (Original) The compound of Claim 1 wherein R^3 is -C_{1-6}alkyl or -C_{3-8}cycloalkyl.

Claim 12 (Original) The compound of Claim 11 wherein R^3 is selected from:

(1) CH_3-;

(2) CH_3CH_2-;

(3) $(CH_3)_2CH$-;

(4) $CH_3CH_2CH_2$-;

(5) $(CH_3)_2CHCH_2$-;

(6) $CH_3CH_2CH_2CH_2$-;

(7) $CH_3CH_2CH_2CH_2CH_2$-; and

(8) bicyclo[2.2.1]heptyl-.

Claim 13 (Original) The compound of Claim 12 wherein R^3 is $(CH_3)_2CHCH_2$-.

Claim 14 (Currently amended) A compound of Claim 1 which is selected from the group consisting of:

Ex	Structure	Ex	Structure
2		3	

Ex	Structure	Ex	Structure
4		5	
6		7	
8		9	
10		11	

Ex	Structure	Ex	Structure
12		13	
14		15	
16		17	

Ex	Structure	Ex	Structure
18		19	
20		21	
22		23	

Ex	Structure	Ex	Structure
24		25	
26		~~27~~	
28		29	

Ex	Structure	Ex	Structure
30		31	
32		33	
34		35	

Ex	Structure	Ex	Structure
36		37	

and pharmaceutically acceptable salts thereof.

Claim 15 (Original) A pharmaceutical composition comprising an effective amount of a compound of Claim 1 and a pharmaceutically acceptable carrier.

Claim 16 (Original) A method for inhibition of β-secretase activity in a mammal in need thereof which comprises administering to the mammal a therapeutically effective amount of a compound of Claim 1.

Claim 17 (Original) A method for treating Alzheimer's disease in a patient in need thereof comprising administering to the patient an effective amount of a compound of Claim 1.